The antihypertensive efficacy of a new controlledrelease preparation of nifedipine developed for once daily administration was investigated in comparison with a standard therapy with sustained-release nifedipine given twice daily in a randomised, open crossover trial. Twenty-two patients with mild to moderate essential hypertension were enrolled. Ambulatory blood pressure monitoring (ABPM) was performed after a wash-out period and after a 3 weeks treatment with 40 mg controlled-release nifedipine once daily and 20 mg sustained-release nifedipine twice daily, respectively. ABPM data were evaluated by conventional linear analysis and by rhythm analysis. Both once daily and twice daily administration of nifedipine significantly reduced systolic blood pressure during the daytime and
Introduction
The dihydropyridine calcium antagonist nifedipine is commonly used in the treatment of hypertension. [1] [2] [3] Its pharmacokinetic profile is characterised by high and rapidly attained maximal plasma concentrations and a short elimination half-life 2,3 thus leading to marked fluctuations in the plasma-concentration-time profile. These properties are linked with a relatively high incidence of vasodilatory side effects 4 and the requirement of multiple daily dosing to maintain therapeutic plasma concentrations over 24 hours. Moreover, the occurrence of high peak drug concentrations is supposed to be associated with a reflexly-induced sympathetic adrenergic activation, which may be responsible for the increased risk of cardiovascular events under long-term treatment with short-acting but not with long-acting calcium antagonists. [5] [6] [7] Furthermore, multiple daily during the night when compared with baseline. The 24-h diastolic blood pressure was significantly decreased by both treatments, but only the once daily regimen significantly lowered both diastolic daytime and night-time means. Comparing systolic and diastolic blood pressures after both treatments, however, no significant differences were obtained. Both nifedipine treatments did neither greatly modify the circadian blood pressure pattern nor reflexly increase heart rate. In conclusion, once daily application of the controlled-release formulation of nifedipine resulted in a consistent and significant blood pressure reduction. Once daily and twice daily medications of nifedipine were about equally effective in lowering the elevated blood pressures.
dosing has been shown to decrease patient's medication compliance. [8] [9] [10] These considerations have led to the development of sustained-release preparations of nifedipine suitable for once daily dosing. 3, [11] [12] [13] [14] [15] A new controlled-release formulation of nifedipine, based on a Geomatrix ® therapeutic system, containing 40 mg nifedipine was generated for once daily administration.
The aim of the present study was to determine the antihypertensive efficacy of this new controlledrelease formulation in comparison with a standard treatment with twice daily application of sustainedrelease nifedipine in mild to moderate hypertensive patients using ambulatory blood pressure monitoring (ABPM).
Patients and methods
This study was performed according to an open, randomised crossover design. The study consisted of three phases with a total duration of 7 weeks. Male and female patients with a history of mild to moderate essential hypertension were eligible for enrollment. Patients were included if their untreated office diastolic blood pressure (DBP) was Ͼ95 mm Hg in three consecutive measurements. Office blood pressure (BP) values were obtained either at the first visit or at the end of the wash-out period in patients previously treated with antihypertensive drugs. Office BP recordings were taken with a conventional sphygmomanometer in the morning between 08.00 h and 09.00 h in sitting position after at least 5 min of rest and separated by 5 min. BP was measured in both arms at the first visit. In case of side differences, the arm with higher values was considered for all further BP recordings. No concomitant therapy with antihypertensive or cardiovascular active drugs was permitted throughout the study.
The study protocol was approved by the ethics committee of the J.W.-Goethe University, Frankfurt am Main, Germany, and written informed consent was obtained from each participant.
Following a wash-out period of at least 1 week patients were randomly allocated to two treatment schedules starting either with 20 mg sustainedrelease nifedipine twice daily (1 tablet orally at 08.00 and at 19.00) or 40 mg controlled-release nifedipine once daily (1 tablet orally at 08.00) for 3 weeks, respectively. ABPM was conducted after the wash-out period (baseline) and after both 3 weeks treatment under hospitalisation. ABPM was performed with a non-invasive auscultatory measuring device with ECG-gating (Tonopor ® , PPG Hellige GmbH, Freiburg, Germany). BP and heart rate were measured in 15-min intervals during daytime (06.00 to 22.00) and in 30-min intervals during night-time (22.00 to 06.00). ABPM recorders were fitted around 07.30 and worn until at least 08.00 the next day.
Medical history, physical examination, 12-lead rest electrocardiogram (ECG) and blood laboratory screening tests as well as urinalysis were performed at entry and at completion of the study. Patients attended the hospital at weekly intervals for evaluation of office BP and heart rate, registration of adverse events and compliance control. Office BP was measured between 07.30 and 09.30 before intake of the study medication. Compliance was tested by pill-counting and by determination of trough plasma concentrations of nifedipine and its main metabolite M1. On each visit during the active treatment periods venous blood samples were collected directly before drug intake (24 ± 1 h following the last dose). Plasma concentrations of nifedipine and M1 were determined by HPLC with UV-detection. 16 On the assumption that a reduction in the 24-h mean of DBP of at least 4 mm Hg will constitute a clinically relevant effect, a sample size of 12 evaluable patients was required to detect a difference with 80% power. Individual ABPM data were evaluated by linear and rhythm analysis by means of a software package including the program ABPM-FIT and, for group evaluation, the program CV-SORT. 17 The linear analysis included calculation of individual 24-h, daytime (06.00 to 22.00) and night-time (22.00 to 06.00) mean values of systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate. In addition, mean values of systolic and diastolic BP were determined from the raw data of the last 3 h of ABPM (05.00 to 08.00).
Rhythm analysis of SBP, DBP and heart rate was performed by fitting Fourier series with a maximum of six harmonics (period lengths: 24, 12, 8, 6, 4.8 and 4 hours) to the ABPM raw data of each patient. The ABPM-FIT program routine contains a test procedure (F-test) to prove the significance of fit. Parameters of rhythm analysis resulting from the significant best fit (ie, fit with number and period lengths of harmonics which reveal the best description of the overall variation of the raw data) were used for all further calculations. The following parameters were derived from the fitted BP and heart rate curves: mesor (rhythm-adjusted 24-h mean), maximum (highest value of the fitted curve), minimum (lowest value of the fitted curve), the times of their occurrences (t Maximum , t Minimum ) and the differences between maximum and minimum (maximum-minimum). In addition, the maximum slope (maximal rate of increase) evaluated from the first derivative of the fitted curve, and the time of its occurrence (t Max slope , restricted from 03.00 to 10.00) were determined. Significance of drug treatment on SBP, DBP and heart rate was tested by either the parametric Student's t-test for paired data or the non-parametric Friedman-test. Changes in t Maximum , t Minimum and t Max slope were tested by Friedman's analysis of variance, followed by the WilcoxonWilcox-test to assess pairwise differences between baseline and treatments and among both treatment schedules. Calculations of variables of linear analysis as well as of all other parameters of rhythm analysis were done by Student's t-test followed by ␣-correction for multiple comparisons according to Bonferroni and Holm. Statistical analyses were performed with the statistical program package BiAS. 18 Unless indicated otherwise, data are presented as mean ± s.d. A P-value of Ͻ0.05 was considered to be significant.
Results
Twenty-two patients were included in this study. Nine patients were withdrawn because of invalid ABPM recordings (three patients), requirement of additional antihypertensive treatment (two patients), and normotensive blood pressure values in the baseline ABPM (two patients). One patient discontinued the trial due to unknown reasons and one patient dropped-out due to adverse events after the first nifedipine dose.
Thirteen patients (8 male, 5 female) with a mean age of 57.3 years (range 38-73 years), a mean height of 167.5 cm (range 154.0-180.0 cm) and a mean weight of 77.5 kg (range 49.0-99.4 kg) completed the study.
At the end of each 3-week treatment period office BP was reduced from 171.1 ± 18.1/101.7 ± 7.4 mm Hg at baseline to 150.0 ± 17.9/88.1 ± 9.9 mm Hg and 157.3 ± 18.8/90.4 ± 13.0 mm Hg after the once daily and the twice daily application of nifedipine, respectively.
An average number of 86 readings (range 61-101) was obtained in the individual ABPM recordings. As shown in Table 1 , both twice daily and once daily nifedipine medication significantly decreased 24-h, daytime and night-time means of SBP. Similarly, 24-h mean values in DBP decreased significantly after both nifedipine treatments, but a significant effect on both daytime and night-time means in DBP was only found after the once daily preparation. Once daily nifedipine application produced a minor reduction in the early morning (05.00 to 08.00) means of SBP and DBP. Twice daily administration lowered only average SBP during this time span (Table 1) . However, both treatment regimens did not significantly affect morning means when compared with baseline values.
All individual 24-h profiles of SBP ( Figure 1 ) and heart rate ( Figure 3 ) displayed significant daily variations under baseline conditions as well as under both nifedipine treatments as determined by rhythm analysis. In three patients no significant circadian rhythm could be observed in at least one out of the three 24-h profiles in DBP. Therefore, the results of rhythm analysis for DBP refer to ABPM recordings of 10 instead of 13 patients (Figure 2 ). The parameters obtained from rhythm analysis of SBP and DBP are compiled in Table 2 . Mean mesors and maximum values of SBP were significantly lowered by both active treatments whereas mesors and maximum values of DBP showed less pronounced reductions, which did not attain statistical significance in comparison to baseline.
Though only the maximum slope of DBP was significantly increased after the twice daily regimen of s.r.: sustained-release; c.r.: controlled-release; SBP: systolic blood pressure; DBP: diastolic blood pressure; *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001 vs baseline.
nifedipine, an overall tendency of a treatmentinduced increase in the maximum slopes in SBP and DBP is apparent after either formulation ( Table 2) .
The maximal BP values occurred earlier under treatment than at baseline (Table 2 ), but the circadian BP pattern was not greatly modified by both nifedipine therapies (see Figures 1 and 2) .
All parameters of SBP and DBP calculated by both linear and rhythm analysis (Tables 1 and 2) were not significantly different between the two treatment regimens.
Heart rate (Table 3, Figure 3) was not affected by either treatment. In general, nifedipine medication was well tolerated. Adverse events (flush, dizziness, palpitation, headache, nausea) were reported by two patients under the twice daily and by one patient under the once daily regimen.
Compliance-control evaluated by pill-counting did not reveal any discrepancy between the units of study medication prescribed and those actually taken. Moreover, mean trough plasma concentrations of nifedipine after twice daily (19.4 ± 14.0 ng/ml) as well as after once daily (28.7 ± 19.7 ng/ml) application exceeded the minimal effective (15 ng/ml) plasma concentration. 
Discussion
The results of the present trial clearly demonstrate that once daily administration of a controlledrelease formulation of nifedipine produced a significant BP reduction in patients with mild to moderate essential hypertension without an effect on heart rate. The antihypertensive efficacy of this new formulation was equivalent to that observed after standard treatment with twice daily application of a sustained-release preparation of nifedipine at the same daily dose. Once-a-day formulations of dihydropyridine calcium antagonists are increasingly available. Various of these controlled-release preparations [11] [12] [13] [14] [15] have been shown to cause a sustained BP control throughout the dosing interval. However, it is difficult to compare the antihypertensive efficacy of all these products due to the different dosages applied (20 to 100 mg/day) and the different methods used to evaluate the effects on BP (office BP, ABPM). In general, most of the studies reported a decrease in BP by nifedipine by about 10%. Previous investigations using ABPM to evaluate the effects of single daily dosing of 30 mg to 60 mg nifedipine GITS found reductions in systolic and diastolic blood pressures in the range of 6% 15 to 14% 12,14 during both daytime as well as during night-time. Thus, our results showing mean reductions in SBP and DBP by 10% and 6% respectively, are in good agreement with these data.
The non-significant BP-lowering effect at the end of the ABPM may indicate a lack in 24-h efficacy. However, previous studies using ABPM up to 48 hours including the second day of treatment showed for both the ␤-adrenoceptor-blocker atenolol 19 and the ACE-inhibitor enalapril 20 that though no significant BP reduction was observed after 20-24 hours after drug intake the effect reappeared the next day off therapy. Consequently, a reliable assess-ment of the duration of the antihypertensive effect cannot be provided by our study design with ABPM restricted to 24 hours.
Both twice daily and once daily nifedipine treatment tended to induce a more pronounced increase in BP during the early morning hours as indicated by greater maximum slope values as compared to baseline. With regard to the higher cardiovascular risk associated with the early morning rise in BP, 21 this might be an unfavourable effect. However, it is premature to draw final conclusions since our findings are derived from a small number of patients and previous investigations did not focus on this point.
In conclusion, the present study provides evidence that the newly developed once daily formulation of nifedipine decreased BP in hypertensive patients to the same extent as obtained by a conventional twice daily formulation. It may be mentioned that besides lowering BP a once-a-day preparation improves patients' compliance. [8] [9] [10] Moreover, there seems to be a decreased risk of cardiovascular events with long-acting than with short-acting calcium antagonists. [5] [6] [7] These considerations may favour a once daily nifedipine formulation in uncomplicated hypertension as also recommended by the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 22 
